The development and enhancement of the collateral circulation in an animal model of lower limb ischaemia.
In an animal model of hind limb ischemia we documented the levels of endogenous basic fibroblast growth factor (bFGF) in control and ischaemic hind limbs, and evaluated the response to the administration of exogenous recombinant bFGF and heparin. Variations in this model were tested for their ability to alter the development of the collateral circulation. Recovery after acute arterial occlusion was significantly delayed by immediate bilateral mirror-image arterial ligations, when compared with either unilateral arterial ligation or delayed contralateral ligations performed after 2 months. If the major veins were also occluded all limbs developed gangrene, tissue loss and a marked delay in the recovery of blood flow, while none of the animals with unilateral arterial ligations developed gangrene. This indicates that the recovery in blood flow during the acute phase in this model is dependent on collateral vessels from the contralateral iliac artery and that major venous occlusion impedes the development of collateral vessels. Lumbar sympathectomy did not alter the recovery of blood flow after arterial occlusion, suggesting that collateral blood flow is not significantly influenced by autonomic neural supply. Following arterial occlusion there was a ten-fold increase in the levels of endogenous bFGF in all ischaemic muscle groups. Intramuscular implantation of bFGF in heparin-sepharose pellets at the time of arterial ligation markedly enhanced the blood flow for 3 weeks compared with untreated ischaemic limbs. A further increment in blood flow occurred if an additional dose of bFGF was administered 4 weeks after ligation.(ABSTRACT TRUNCATED AT 250 WORDS)
Chleboun
J O
JO
University Department of Surgery, Repatriation General Hospital, Nedlands, Western Australia.
Martins
R N
RN
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000503:physiopathology; D003097:Collateral Circulation / Q000187:drug effects*; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000502:physiology; D006493:Heparin / Q000008:administration & dosage*; D006614:Hindlimb / Q000098:blood supply*; D007511:Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012685:Sepharose / Q000008:administration & dosage
D016222:Fibroblast Growth Factor 2; D006493:Heparin; D012685:Sepharose